-
公开(公告)号:US06742544B2
公开(公告)日:2004-06-01
申请号:US10092035
申请日:2002-03-06
IPC分类号: F16K1122
CPC分类号: F16K99/0001 , F15C5/00 , F16K7/14 , F16K27/003 , F16K99/0015 , F16K99/0023 , F16K99/0059 , F16K2099/0074 , F16K2099/0076 , F16K2099/008 , G01N30/20 , G01N2030/205 , Y10T137/87893
摘要: A novel gas injection valve for injecting discrete charges of gas into a mobile phase or carrier stream is provided. Injection valves of the invention comprise a plurality of microvalves capable of receiving gas at different pressures and emitting discrete charges of gas at approximately the same pressure. The invention further provides for parallel injection valve arrays capable of injecting multiple samples substantially simultaneously and a method of injecting discrete gas samples at a controlled pressure to a high-resolution gas chromatograph.
摘要翻译: 提供了一种用于将离散的气体注入流动相或载流子的新颖的气体注入阀。 本发明的注射阀包括能够接收不同压力的气体并以大致相同的压力发射离散的气体的多个微型阀。 本发明还提供了能够基本上同时喷射多个样品的平行喷射阀阵列以及将受控压力的离散气体样品注入高分辨率气相色谱仪的方法。
-
公开(公告)号:US06610742B1
公开(公告)日:2003-08-26
申请号:US09631655
申请日:2000-08-03
IPC分类号: A61K3120
CPC分类号: C07C57/42 , A61K31/192 , A61K31/195 , A61K31/352 , A61K31/353 , A61K31/382 , A61K31/385 , A61K31/4184 , A61K31/4188 , A61K31/4439 , A61K31/551 , C07C57/48
摘要: Retinoids with retinoid receptor antagonistic activity, pharmaceutically acceptable salts and pharmaceutically acceptable hydrolyzable esters thereof, have been found efficacious in treating T-helper cell type 2 (Th2)-mediated immune diseases, such as immunoglobulin E (IgE)-mediated allergic diseases.
-
公开(公告)号:US5801253A
公开(公告)日:1998-09-01
申请号:US776087
申请日:1997-01-21
IPC分类号: A01N20060101 , A61K31/07 , A61K31/19 , A61K31/215 , A61K31/38 , A61K31/381 , A61P3/02 , A61P17/00 , A61P35/00 , A61P35/02 , A61P43/00 , C07C45/29 , C07C45/63 , C07C47/235 , C07C47/238 , C07C47/24 , C07C47/277 , C07C51/09 , C07C57/02 , C07C57/50 , C07C57/62 , C07C63/00 , C07C67/343 , C07C69/618 , C07C69/65 , C07C69/734 , C07D333/24 , C07F9/40 , C07F9/48 , C07F9/54 , C07D333/08 , C07C69/76 , C07C233/00
CPC分类号: C07F9/4056 , C07C45/29 , C07C45/298 , C07C45/63 , C07C47/24 , C07C47/277 , C07C57/50 , C07D333/24 , C07C2101/16
摘要: Compounds of formula (I) wherein R.sup.1 -R.sup.7, R.sup.10, X and the dotted bond have the meaning given in the specification, bind selectively to retinoid RXR receptors and are useful as antiproliferative agents for dermatological and oncological indications.
摘要翻译: PCT No.PCT / EP95 / 03021 Sec。 371日期1997年1月21日 102(e)日期1997年1月21日PCT提交1995年7月29日PCT公布。 公开号WO96 / 05165 日期1996年2月22日其中R1-R7,R10,X和点键具有说明书中给出的含义的式(I)化合物选择性地结合于类视黄醇RXR受体,并且可用作皮肤病学和肿瘤学适应症的抗增生剂。
-
公开(公告)号:US5391766A
公开(公告)日:1995-02-21
申请号:US57949
申请日:1993-05-05
申请人: Michael Klaus , Peter Mohr
发明人: Michael Klaus , Peter Mohr
IPC分类号: A61K31/38 , A61K31/381 , A61K31/382 , A61P17/00 , A61P37/06 , C07D333/54 , C07D335/06 , C07D337/08
CPC分类号: C07D333/54 , C07D335/06 , C07D337/08
摘要: Compounds of the formula ##STR1## in which X is --S--, --SO-- or --SO.sub.2 --; R.sup.1 is C.sub.7-10 -alkyl or C.sub.7-10 -alkoxy; R.sup.2 is a residue of the formula ##STR2## R.sup.3 is carboxy or lower-alkoxycarbonyl; and n is an integer of 1, 2 or 3; and salts of carboxylic acids of formula I can be used for the treatment of autoimmune diseases and diseases having a strong immunological component, such as psoriasis.
摘要翻译: 其中X是-S-,-SO-或-SO 2 - 的式I的化合物; R1是C7-10-烷基或C7-10-烷氧基; R 2是下式的残基:(a)或(b)R 3是羧基或低级烷氧基羰基; n为1,2或3的整数; 式I的羧酸盐可用于治疗具有强免疫组分的自身免疫性疾病和疾病,例如牛皮癣。
-
公开(公告)号:US5250562A
公开(公告)日:1993-10-05
申请号:US829666
申请日:1992-02-03
申请人: Michael Klaus , Peter Mohr , Ekkehard Weiss
发明人: Michael Klaus , Peter Mohr , Ekkehard Weiss
IPC分类号: C07C211/10 , C07C317/18 , C07C323/12 , C07C323/25 , C07D295/092 , C07D295/13 , A61K31/40 , C07D207/06
CPC分类号: C07D295/088 , C07C211/10 , C07C317/18 , C07C323/12 , C07C323/25 , C07D295/13 , C07C2102/08 , C07C2102/10
摘要: Compounds of the formula ##STR1## wherein R.sup.1 and R.sup.2 each independently are lower-alkyl; or together are alkylene with 3-5 C-atoms in a straight chain; one of the residues R.sup.3 and R.sup.4 is hydrogen and the other is hydrogen or lower-alkyl; R.sup.6 and R.sup.7 are hydrogen or lower-alkyl; R.sup.5 and R.sup.8 are hydrogen, lower-alkyl, lower-alkoxy or halogen; X signifies --O--, --S--, --SO--, --SO.sub.2 -- or --NR.sup.9 ; R.sup.9 is hydrogen, lower-alkyl or acyl; Y is --S(O).sub.m R.sup.10 or --NHet and, where X is --NR.sup.9 --, --S--, --SO-- or --SO.sub.2 --, also --N(R.sup.11).sub.2 or --OR.sup.12 ; R.sup.10 is lower-alkyl; R.sup.11 and R.sup.12 are hydrogen, lower-alkyl or acyl; --NHet is a 5-8 membered, saturated or unsaturated, monocyclic heterocycle attached via a N-atom; n is 2, 3 or 4 and m is 0, 1 or 2, are described. The compounds of formula I are useful as agents for the treatment of disorders such as neoplasms, dermatoses or ageing of the skin.
摘要翻译: 式Ⅰ的化合物,其中R 1和R 2各自独立地为低级烷基; 或一起是直链中具有3-5个C原子的亚烷基; 残基R3和R4之一是氢,另一个是氢或低级烷基; R6和R7是氢或低级烷基; R5和R8是氢,低级烷基,低级烷氧基或卤素; X表示-O - , - S - , - SO - , - SO 2 - 或-NR 9; R9是氢,低级烷基或酰基; Y是-S(O)m R 10或-NHet,且其中X是-NR 9 - , - S - , - SO-或-SO 2 - ,以及-N(R 11)2或-OR 12; R10为低级烷基; R 11和R 12是氢,低级烷基或酰基; -NHet是通过N-原子连接的5-8元饱和或不饱和的单环杂环; n为2,3或4,m为0,1或2。 式I的化合物可用作治疗诸如赘生物,皮肤病或皮肤老化的病症的药剂。
-
公开(公告)号:US4935560A
公开(公告)日:1990-06-19
申请号:US467291
申请日:1990-01-16
申请人: Michael Klaus , Peter Loeliger , Peter Mohr , Ekkehard Weiss
发明人: Michael Klaus , Peter Loeliger , Peter Mohr , Ekkehard Weiss
IPC分类号: A61K31/01 , A61K31/015 , A61K31/02 , A61K31/035 , A61K31/045 , A61K31/12 , A61K31/215 , C07C13/45 , C07C13/465 , C07C13/48 , C07C15/24 , C07C15/52 , C07C15/58 , C07C25/24 , C07C25/28 , C07C35/32 , C07C35/36 , C07C39/23 , C07C43/215 , C07C43/23 , C07C45/72 , C07C49/683 , C07C49/697 , C07C49/747 , C07C69/157 , C07C205/06
CPC分类号: C07C205/06 , A61K31/015 , A61K31/035 , C07C13/465 , C07C13/48 , C07C25/24 , C07C35/32 , C07C35/36 , C07C39/23 , C07C43/215 , C07C43/23 , C07C45/72 , C07C49/683 , C07C49/697 , C07C49/747 , C07C2102/08 , C07C2102/10
摘要: Novel styryl-tetrahydromaphthalene and indane derivatives useful for treating neoplasms and dermatoses.
-
公开(公告)号:US4876349A
公开(公告)日:1989-10-24
申请号:US72075
申请日:1987-07-10
申请人: Michael Klaus , Ekkehard Weiss
发明人: Michael Klaus , Ekkehard Weiss
IPC分类号: A61K31/33 , A61K31/425 , A61K31/426 , A61K31/44 , A61K31/4402 , A61K31/4406 , A61K31/4409 , A61K31/4418 , A61K31/496 , A61K31/505 , A61P17/00 , A61P29/00 , A61P35/00 , A61P37/08 , C07D213/16 , C07D233/58 , C07D233/64 , C07D239/26 , C07D261/08 , C07D263/32 , C07D277/22 , C07D307/36 , C07D333/08
CPC分类号: C07D213/16 , C07D239/26 , C07D307/36 , C07D333/08
摘要: The compounds of the formula ##STR1## wherein X and Y are independently --CH.sub.2 -- or >C(CH.sub.3).sub.2 ; Z is --CHR.sup.8 --, >Co, >CR.sup.8 OR.sup.7 , --CHR.sup.8 --CHR.sup.8 --, --CHOR.sup.7 --CH.sub.2 --, --CO--CHOR.sup.7 or --CHOR.sup.7 --CHOR.sup.7 --R.sup.1 is a 5- or 6-membered, monocyclic heterocyclic group which optionally can be C-substituted by halogen, lower-alkyl, lower-alkoxy, acyloxy, nitro, hydroxy, amino, lower-alkylamino or di-lower-alkylamino and/or which can be substituted on a ring --NH-- group by lower-alkyl; R.sup.2 and R.sup.3 are independently hydrogen, lower-alkyl, trifluoromethyl or halogen and one of R.sup.2 and R.sup.3 always is trifluoromethyl or lower-alkyl; R.sup.4 and R.sup.5 are independently hydrogen, alkyl, alkoxy or halogen; R.sup.6 is hydrogen, lower-alkyl or --OR.sup.7 ; R.sup.7 is hydrogen, lower-alkyl or acyl; R.sup.8 is hydrogen or lower-alkyl; and R.sup.7 and R.sup.8 can be the same or different from one another.are useful for the treatment of neoplasms and dermatoses in mammals. The compounds can be manufactured from a corresponding bicyclic component and a heterocyclic component containing the residue R.sup.1 by a Wittig, Horner or Grignard reaction and the optional subsequent transformation of reactive groups.
摘要翻译: 下式的化合物其中X和Y独立地是-CH 2 - 或> C(CH 3)2; Z是-CHR8-,> Co,> CR8 OR7,-CHR8-CHR8 + 13,-CHOR7-CH2-,-CO-CHOR7或-CHOR7-CHOR7-R1是5-或6-元单环杂环基,其中 任选地可以被卤素,低级烷基,低级烷氧基,酰氧基,硝基,羟基,氨基,低级烷基氨基或二 - 低级 - 烷基氨基和/或可以被低级烷基氨基取代的环-NH-基团上C -烷基; R2和R3独立地是氢,低级烷基,三氟甲基或卤素,R2和R3之一总是三氟甲基或低级烷基; R4和R5独立地是氢,烷基,烷氧基或卤素; R6是氢,低级烷基或-OR7; R7是氢,低级烷基或酰基; R8是氢或低级烷基; 并且R 7和R 8可以相同或不同。 可用于治疗哺乳动物的肿瘤和皮肤病。 化合物可以由对应的双环组分和含有残基R1的杂环组分通过Wittig,Horner或Grignard反应和任选的随后的反应性基团的转化来制备。
-
公开(公告)号:US07354931B2
公开(公告)日:2008-04-08
申请号:US10960372
申请日:2004-10-07
申请人: Michael Klaus , Jean-Marc Lapierre
发明人: Michael Klaus , Jean-Marc Lapierre
IPC分类号: C07D251/02 , A61K31/47
CPC分类号: C07D335/06 , C07D215/12 , C07D311/58 , C07D409/04 , C07D409/12
摘要: The current invention provide novel heterocyclic retinoid compounds, methods of treating or preventing chronic obstructive pulmonary disease, cancer and dermatological disorders, pharmaceutical compositions suitable for the treatment or prevention of these disorders and methods for delivering formulations of these retinoids to a mammal having these disorders.
摘要翻译: 本发明提供了新颖的杂环类视黄醇化合物,治疗或预防慢性阻塞性肺疾病,癌症和皮肤疾病的方法,适于治疗或预防这些病症的药物组合物以及将这些类视色素的制剂输送到具有这些疾病的哺乳动物的方法。
-
公开(公告)号:US20060183737A1
公开(公告)日:2006-08-17
申请号:US11402501
申请日:2006-04-12
IPC分类号: A61K31/551 , A61K31/4439 , A61K31/4188 , A61K31/382 , A61K31/385 , A61K31/353 , A61K31/195 , A61K31/192
CPC分类号: C07C57/42 , A61K31/192 , A61K31/195 , A61K31/352 , A61K31/353 , A61K31/382 , A61K31/385 , A61K31/4184 , A61K31/4188 , A61K31/4439 , A61K31/551 , C07C57/48
摘要: Retinoids with retinoid receptor antagonistic activity, pharmaceutically acceptable salts and pharmaceutically acceptable hydrolyzable esters thereof, have been found efficacious in treating T-helper cell type 2 (Th2)-mediated immune diseases, such as immunoglobulin E (IgE)-mediated allergic diseases.
-
10.
公开(公告)号:US06300350B1
公开(公告)日:2001-10-09
申请号:US09691967
申请日:2000-10-18
IPC分类号: A61K3144
CPC分类号: A61K31/44 , A61K31/00 , A61K31/192 , A61K31/195 , A61K31/24 , A61K31/352 , A61K31/355
摘要: This invention provides methods of treating emphysema and other diseases associated with alveolar damage by treatment with an RAR&ggr; selective agonist. In another aspect, this invention provides methods of promoting tropoelastin gene expression and alveolar matrix repair by contacting the pulmonary intestitial fibroblast with an RAR agonist, preferably an RAR&ggr; selective agonist.
摘要翻译: 本发明提供了通过用RARγ选择性激动剂治疗来治疗与肺泡损伤相关的肺气肿和其它疾病的方法。 另一方面,本发明提供通过使肺内脏成纤维细胞与RAR激动剂,优选RARγ选择性激动剂接触来促进托普拉斯他汀基因表达和肺泡基质修复的方法。
-
-
-
-
-
-
-
-
-